Fundraising Fox3B Future Health Fund — Full Portfolio
24 tracked investments · listed companies and verified rows first
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investorsAlly Bridge GroupDecheng CapitalVivo CapitalAvoro VenturesOrbiMed
Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesBethesda, US
Gene Mack(President, Chief Executive Officer and Director)in
BoardMarianne Bjordal(Director)inLorenzo Leoni(Director)inKhalid Islam(Director)Jeffrey Riley(Director)Eric I. Richman(Executive Officer, Director)
Co-investorsTiVenture SAAllele Capital Partners
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investorsIndustrifondenNovo HoldingsPureos BioventuresSound Bioventures
Greenbone Ortho develops orthopedic medical products and constantly pursues clinical innovation and new applications.
BiotechCleantechHealthtechMedical DevicesNew MaterialsFaenza, IT
Anna Tampieri(Chairman & Director)Saverio Gellini(Chief Executive Officer & Director)inAndrea Cha(Chief Operating Officer)inVanessa Bonomi(Chief Quality Regulatory Officer)inPaolo Sala(Chief Financial Officer)inSusanna Salvagno(Chief Medical & Scientific Officer)in
Co-investorsCDP Venture CapitalItalian Angels for Growth
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatRoberto De Ponti· per SEC Form D
Co-investorsCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture PartnersBering Capital+5 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investorsCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalPanacea VentureSeventure Partners
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investorsAlbionVCBioGeneration VenturesEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund
BiotechPlymouth Meeting, US
Niranjan Y. Sardesai(Executive Officer, Director)inLaurent Humeau(Director)James Eadie(Director)Samuel Broder(Director)Sangwoo Lee(Director)Casey Cunningham(Director)
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkefM VenturesVI PartnersXGEN VentureJohnson & Johnson Innovation – JJDC
Kither Biotech is a clinical-stage biotech company developing inhaled cell signal transduction modulators targeting the PI3Kγ signaling axis for respiratory diseases such as COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, and idiopathic pulmonary fibrosis.
BiotechHealthtech
Co-investorsCDP Venture CapitalClaris VenturesElysia CapitalItalian Angels for Growth
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Justin (Jay) File(CEO, CFO)inKevan E. Clemens(Director)
Co-investorsAisling CapitalGSRNew Enterprise Associates (NEA)Primitive VenturesAmzak HealthBiotechnology Value Fund+1 more
Neophore develops a small-molecule therapeutic that transiently inhibits DNA Mismatch Repair (MMR) to convert MMR-proficient tumours into an MMR-deficient state, making them responsive to cancer immunotherapy.
AI & Machine LearningBiotechLongevity
Co-investorsAstellas Venture Management LLCClaris VenturesItalian Angels for GrowthLIFTTNeva Sgr.
On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.
BiotechHealthtechMedical Devices
Bill Peters(President, Chief Executive Officer, and Board Member)inRod MacLeod(Chief Financial Officer)inTommy Lee(Senior Vice President of Clinical Operations)inCatherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)inScott Huennekens(Executive Chairperson)in
Co-investorsCerity Partners VenturesElevate VenturesH.I.G. CapitalH.I.G. HealthBridge PartnersH.I.G. BioHealth Partners
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
BiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inLuis A. Diaz, Jr.(Executive Officer, Director, Promoter)Sam Angiuoli(Executive Officer)inSian Jones(Executive Officer)inLisa Kann(Executive Officer)inAnthony Newton(Executive Officer)
Co-investorsCatalio Capital Management, LPCo-Win VenturesNew Enterprise Associates (NEA)Windham Capital PartnersVensana Capital
QuantuMDx develops point-of-care molecular diagnostics platforms and assays for detecting infectious diseases including sexually transmitted infections, antimicrobial resistance, respiratory viruses, and other pathogens.
Digital HealthHealthtechMedical DevicesNewcastle upon Tyne, GB
Elaine Warburton(Co-Founder and former CEO)
Co-investorsAdjuvoDEFTA Partners
Roca Therapeutics develops first-in-class small molecule therapies for patients with neovascular retinal diseases.
BiotechHealthtechMedical DevicesNice, FR
Obtained U.S.
Co-investorsAMR Action Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
FORE US BioAMAL Therapeutics SAGenEpNavion NeurosciencesNovellus
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.